MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics - Report - MDSpire

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • By

  • Rocío Maseda

  • María Carmen Arriba

  • Lucía Martínez-Santamaría

  • Eva Jiménez

  • Sara Herráiz-Gil

  • Nuria Illera

  • Lucía Quintana-Castanedo

  • Marta García

  • Susana Suárez-Sancho

  • Rosa Yáñez

  • Isabel Pérez-Conde

  • Marta Carretero

  • Magdalena Martínez-Queipo

  • Raquel de Paz

  • Carlos León

  • Víctor Jiménez-Yuste

  • Alberto M. Borobia

  • Ángeles Vicente

  • Su M. Lwin

  • John A. McGrath

  • María Eugenia Fernández-Santos

  • Nora Butta

  • Rosa Sacedón

  • Marcela del Río

  • Raúl de Lucas

  • María José Escámez

  • May 5, 2026

  • 0 min

Share

Clinical Report: MesenSistem-EB: Systemic Haploidentical MSC Treatment for RDEB

Overview

{'add': 'Elaborate on the predictive value of MCP1 and sCD40L.'}

Background

{'add': 'List current treatment options for RDEB.'}

Data Highlights

{'update': 'Ensure all relevant parameters are included in the table.'}

Key Findings

{'add': 'Discuss the clinical implications of immune cell changes.'}

Clinical Implications

{'add': 'Provide specific monitoring recommendations for biomarkers.'}

Conclusion

{'add': 'Highlight the need for research into MSC therapy mechanisms.'}

References

  1. Frontiers, 2026 -- MesenSistem-EB: Systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics
  2. Management of oesophageal strictures in inherited epidermolysis bullosa: a clinical practice guideline - PubMed
  3. Clinical Rheumatology — Application of Stem Cell Therapy for Systemic Sclerosis Management
  4. Bone Marrow Transplantation — Highlights from the 46th Annual Conference of the European Society for Blood and Marrow Transplantation: Award Recipients
  5. Clinical Research in Cardiology — Identification of a new desmoplakin mutation linked to juvenile biventricular cardiomyopathy, left ventricular non-compaction, and acantholytic palmoplantar keratoderma
  6. Bone Marrow Transplantation — The 47th Annual Conference of the European Society for Blood and Marrow Transplantation: Recognition of Van Bekkum Award Recipients
  7. ZEVASKYN | FDA
  8. Management of oesophageal strictures in inherited epidermolysis bullosa: a clinical practice guideline - PubMed
  9. Frontiers | MesenSistem-EB: Systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

Original Source(s)

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • by Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, Eva Jiménez, Sara Herráiz-Gil, Nuria Illera, Lucía Quintana-Castanedo, Marta García, Susana Suárez-Sancho, Rosa Yáñez, Isabel Pérez-Conde, Marta Carretero, Magdalena Martínez-Queipo, Raquel de Paz, Carlos León, Víctor Jiménez-Yuste, Alberto M. Borobia, Ángeles Vicente, Su M. Lwin, John A. McGrath, María Eugenia Fernández-Santos, Nora Butta, Rosa Sacedón, Marcela del Río, Raúl de Lucas, María José Escámez

  • May 5, 2026

Related Content

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma